Mifegyne (Mifepristone)

Mifepristone acts as a competitive antagonist at progesterone receptors in the uterus. By blocking progesterone, it causes the uterine lining to break down and the embryo to detach. The drug also sensitizes the uterus to prostaglandins, enhancing uterine contractions that help complete the termination process.

The specific dose of Mifegyne is determined by the prescribing clinician based on the patient’s clinical situation, gestational age, and local guidelines. A qualified health‑care professional will decide the appropriate regimen and any follow‑up medication required.

Mifegyne is indicated for the intentional termination of early pregnancy and is contraindicated for use in an ongoing pregnancy other than for that purpose. It is not recommended for breastfeeding women because the drug can be excreted in breast milk and may affect the infant.

To order Mifegyne, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative to Mifegyne is misoprostol used alone, which induces uterine contractions but lacks the progesterone‑blocking effect of mifepristone. Combining mifepristone with misoprostol generally results in higher efficacy, lower surgical‑intervention rates, and a more predictable clinical course compared with misoprostol alone.

Mifegyne tablets should be stored at ambient temperature, preferably below 25 °C, in their original packaging to protect them from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Mifegyne is taken as an oral tablet under direct supervision of a qualified health‑care provider. The tablet is swallowed with water, and the patient is monitored for response and any adverse effects. Subsequent medication, such as misoprostol, may be prescribed according to the treatment protocol.

Serious risks include severe hemorrhage, infection, allergic reactions, and incomplete abortion that may require surgical intervention. Patients should be advised to seek immediate medical attention if they experience heavy bleeding, fever, severe abdominal pain, or signs of an allergic reaction.

Mifegyne is contraindicated in women with chronic adrenal insufficiency, those receiving long‑term systemic corticosteroids, individuals with known hypersensitivity to mifepristone, and in pregnancies beyond the approved gestational limit. It should also be avoided in patients with certain uterine abnormalities or severe bleeding disorders.